1Bamabei A, Ferretti E, Baldelli R, et al.Hurthle cell turnouts of the thyroid. Personal experience and review of the literature[J]. Acta Otorhinolaryngol Ital,2009 , 29(6):305-311.
3Prasad ML, Pellegata NS, Huang Y, et.al.Galectin-3, fibronectin-l, CITED-I, HBMEI and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors [J ]. Mod Pathol, 2005, 18(1):48-57.
4Seognamiglio T, Hyjek E, Kao J, et al.Diagnostic usefulness of HBMEI, galectin-3, CK19, and CITEDI and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma[J]. Am J Clin Pathol, 2006, 126(5): 700-708.
5Nasr MR, Mukhopadhyay S, Zhang S, et al. lmmunohistochemical markers in diagnosis of papillary thyroid cawinoma: Utility of HBME1 combined with CKI9 immunastaining[J]. Mnd Pathol, 2006, 19(12):1631-1637.
6Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a mela-analysis [ J ]. Cancer, 2007, 110( 1):38-46.
7Ruggieri M, Zullino A, Straniero A, et al.Is minimally invasive surgery appropriate for small differentiated thyroid carcinomas? [J]. Surg Today,2010 ,40(5):418-422.
3Carcangiu ML, Bianchi S, Savino D, et al. Follicular Hurthle cell tumors of the thyroid gland [ J ]. Cancer, 1991,68 ( 9 ) : 1944 - 1953.
4Sugino K,Ito K,Mimura T,et al. Hurthle cell tumor of the thyroid : analysis of 188 cases [ J ]. World J Surg, 2001,25 ( 9 ) : 1160 - 1163.
5Lopez-Penabad L, Chiu AC, Hoff AO, et al. Prognostic factors in patients with Harthle cell neoplasms of the thyroid[J]. Cancer, 2003,97(5) :1186 - 1194.
6Grant CS. Operative and postoperative management of the patient with follicular and Hurthle cell carcinoma. Do they differ? [ J]. Surg Clin North Am, 1995,75 ( 3 ) :395 -403.
7[12]Lazarus JH, Obuobie K. Thyroid disorder-an update. Postgrad Med J, 2000, 76(899): 529
8[13]Quadro L, Panariello L, Salvatore D, et al. Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab, 1994, 79(2): 590
9[14]Bongarzone I, Pierotti MA, Monzini N,et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene, 1989, 4(12): 1457
10[15]Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med, 2002, 43(9): 1188
